All electric vehicle makers are experiencing supply chain and cost issues, but Tesla has an obvious lead on the rest.
It appears Frontier's offer for the discount airline is expected to win out.
A recent downgrade by an analyst sent the stock tumbling.
Its latest COVID-19 vaccine appears to be effective against the most common viral variants.
A buyout ends Epizyme's 15-year tenure as an independent biopharma.
Are these opportunities for long-term investors?
A analyst downgrade hurt cruise line stocks this morning.
